Ovarian Cancer: Recurrence

Many women who've been treated for ovarian cancer will have a recurrence within five years ... there are many treatment options, some very new.

SN Local - Explore expertise and community near you:

Recurrence

Dealing with Recurrence in Ovarian Cancer

Eighty percent of women with ovarian cancer enter into remission. However, during the next five years, 70 to 80 percent of those women may have a “recurrence,” when the cancer comes back, according to Dr. Beth Karlan, a gynecologic oncologist at the UCLA Medical Center whose skill as a clinician is noted among her coll... Read More

Dr. Beth Karlan UCLA Medical Center

Recurrence: What Are The Options When the Cancer Returns?

SEE MORE

When Ovarian Cancer Comes Back-- The Standard of Care Treatment

Dr. Rebecca Arend
University of Alabama-Birmingham

Recurrent Ovarian Cancer Treatment-- Is Your Disease "Platinum-Sensitive"?

Dr. Oliver Dorigo
Stanford University Medical Center

Women with Recurrent Ovarian Cancer Are Living Longer on PARP Inhibitors

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Fighting "Platinum Resistant" Ovarian Cancer

Dr. Bobbie Rimel
Cedars-Sinai Medical Center

Recurrence: What Are The Options When the Cancer Returns?

Recurrence: PARP Inhibitors: An Important Treatment on the Cutting Edge

Dr. Oliver Dorigo

Stanford University Medical Center

Weighing the Benefits of PARP Inhibitors

Dr. Emese Zsiros
Roswell Park Comprehensive Cancer Center

What's it Like to Take a PARP Inhibitor?

Dr. Rebecca Arend
University of Alabama-Birmingham

Who can have PARP Inhibitors?

Dr. Oliver Dorigo
Stanford University Medical Center

Managing Side Effects: Which PARP Inhibitor Is Right For Me?

Dr. Oliver Dorigo
Stanford University Medical Center

Costs and Barriers to Getting PARP Inhibitors

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

When PARP Inhibitors Stop Working: Testing Combinations

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Dr. Oliver Dorigo

Stanford University Medical Center

Weighing the Benefits of PARP Inhibitors

Dr. Emese Zsiros
Roswell Park Comprehensive Cancer Center

What's it Like to Take a PARP Inhibitor?

Dr. Rebecca Arend
University of Alabama-Birmingham

Who can have PARP Inhibitors?

Dr. Oliver Dorigo
Stanford University Medical Center

Managing Side Effects: Which PARP Inhibitor Is Right For Me?

Dr. Oliver Dorigo
Stanford University Medical Center

Costs and Barriers to Getting PARP Inhibitors

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

When PARP Inhibitors Stop Working: Testing Combinations

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Recurrence: My Cancer's Come Back. Should I Try A Clinical Trial?

The Option of Clinical Trial

Dr. Dana Chase
Arizona Oncology

Why I'd Choose a Clinical Trial For Myself

Dr. Ben Neel
NYU Perlmutter Cancer Center

Clinical Trials Can Be Life-Saving

Dr. Beth Karlan
UCLA Medical Center

Clinical Trials and What Statistics Really Mean

Dr. Scott Strome
University of Maryland

Promising Immunotherapy Trials for Ovarian Cancer

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Ovarian Cancer - The Importance of Increasing Diversity in Clinical Trials

Dr. Dana Chase
Arizona Oncology

The Option of Clinical Trial

Dr. Dana Chase
Arizona Oncology

Why I'd Choose a Clinical Trial For Myself

Dr. Ben Neel
NYU Perlmutter Cancer Center

Clinical Trials Can Be Life-Saving

Dr. Beth Karlan
UCLA Medical Center

Clinical Trials and What Statistics Really Mean

Dr. Scott Strome
University of Maryland

Promising Immunotherapy Trials for Ovarian Cancer

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Ovarian Cancer - The Importance of Increasing Diversity in Clinical Trials

Dr. Dana Chase
Arizona Oncology

Recurrence: Immunotherapy as a Weapon Against Recurrence

Dr. Emese Zsiros

Roswell Park Comprehensive Cancer Center

Immunotherapy in Recurrence

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Overcoming Hurdles in Immunotherapy

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Promising Immunotherapy Trials for Ovarian Cancer

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Exciting Developments in Immunotherapy for Ovarian Cancer

Dr. David Cibula
First Faculty of Medicine - Charles University

Dr. Emese Zsiros

Roswell Park Comprehensive Cancer Center

Immunotherapy in Recurrence

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Overcoming Hurdles in Immunotherapy

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Promising Immunotherapy Trials for Ovarian Cancer

Dr. Kunle Odunsi
Roswell Park Comprehensive Cancer Center

Exciting Developments in Immunotherapy for Ovarian Cancer

Dr. David Cibula
First Faculty of Medicine - Charles University

>

SN Local - Explore Ovarian Cancer expertise and community near you: